OASMY
US OTC
Oasmia Pharmaceutical AB (publ)
Overview
OASMY
Symbol
US OTC
Exchange
About stock

Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer.

Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel that has completed pre-clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer. The company also provides combination therapies, such as XR-19 for various forms of cancer, including ovarian, first-line breast, prostate, and lung cancer. In addition, its animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma.

Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Uppsala, Sweden.

Oasmia Pharmaceutical AB (publ) dividend calculator
Report issue